: After high hopes for Merck’s COVID-19 pill, Wall Street now expects a ‘tepid’ authorization
Marketwatch -

It’s likely that Merck’s COVID-19 pill will be authorized in the U.S. this month but it's expected to be restricted to certain high-risk people.

Read this story at

Loading...

Related Articles